Shanghai Dahua Pharmaceutical Co., Ltd, along with DKT WomanCare announced to reduce the price of, a two-rod contraceptive implant Levoplant that was recently approved to enhance women's reproductive health autonomy. Furthermore, it will now cost qualified buyers around USD 6 which will aid in increasing access to a high-quality contraceptive for those who need it the most and will make it easier for people who require access to quality contraception.
Contraline, Inc. announced to investment of over USD 7 million for the creation of the first injectable hydrogel-based implanted male contraceptives to create a long-acting, reversible male contraceptive that gives more individuals more choices for family planning and changes how people think about contraception.
Teva Pharmaceutical Industries Ltd. introduced a Generic Version of NuvaRing intended for use by women of reproductive age that combines estrogen and progestin to prevent conception. Furthermore, the product is an essential addition to Teva's generic product line which must be worn for three weeks.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 5300
Published Date: Oct 09, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
Rising count of unintended pregnancies and the rising governmental initiative to utilize contraceptive procedures are the major factors driving the growth of the market.
The market size of subdermal contraceptive implants is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2024-2036.
The major players in the market are Shanghai Dahua Pharmaceutical Co., Ltd, Bayer AG, Wyeth Pharmaceuticals, Baxter, Gerresheimer AG, Pfizer, Inc., Novartis AG, Schott AG, Eli Lilly and Company, and others.
The etonogestrel implant segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.
The market in the North American region is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.